<\/b><\/p>\n
<\/b><\/p>\n
FRIDAY, Aug. 28, 2020 (HealthDay News) — Among hospitalized patients with COVID-19, anticoagulation (AC) is associated with reduced mortality and intubation, according to a study published online Aug. 26 in the Journal of the American College of Cardiology<\/i>.<\/p>\n
Girish N. Nadkarni, M.D., M.P.H., from the Mount Sinai COVID Informatics Center in New York City, and colleagues examined the association between AC and in-hospital outcomes and postmortem findings among 4,389 patients with COVID-19.<\/p>\n
The researchers found that therapeutic and prophylactic AC were associated with lower in-hospital mortality (adjusted hazard ratios [aHRs], 0.53 [95 percent confidence interval (CI), 0.45 to 0.62] and 0.50 [95 percent CI, 0.45 to 0.57], respectively) and intubation (aHRs, 0.69 [95 percent CI, 0.51 to 0.94] and 0.72 [95 percent CI, 0.58 to 0.89], respectively) compared with no AC. There was no statistically significant difference between therapeutic and prophylactic AC when initiated \u226448 hours from admission (aHR, 0.86; 95 percent CI, 0.73 to 1.02; P = 0.08). A total of 89 patients had major bleeding (2 percent); of these patients, 27, 33, and 29 were on therapeutic, prophylactic, and no AC, respectively (3.0, 1.7, and 1.9 percent, respectively). Forty-two percent of the 26 autopsies had thromboembolic disease not clinically suspected, and 27 percent of those (three patients) were on therapeutic AC.<\/p>\n
“These observational analyses were done with the highest level of statistical rigor and provide exciting insights into the association of anticoagulation with critical in-hospital outcomes of mortality and intubation,” Nadkarni said in a statement. “Ultimately we hope this work will lead to improved outcomes and treatment for COVID-19 patients.”<\/p>\n
Several authors disclosed financial ties to the biopharmaceutical industry.<\/p>\n
Abstract\/Full Text (subscription or payment may be required)<\/a><\/p>\n <\/i><\/p>\n